The tumor suppressor p53 transcriptionally regulates a large number of target genes that may aect cell growth and cell death pathways. To better understand the role of p53 loss in tumorigenesis, we have developed a mouse mammary cancer model, the Wnt-1 TG/p53 model. Wnt-1 transgenic females that are p537/7 develop mammary adenocarcinomas that arise sooner, grow faster, appear more anaplastic, and have higher levels of chromosomal instability than their Wnt-1 transgenic p53+/+ counterparts. In this study, we used several assays to determine whether the presence or absence of p53 aects gene expression patterns in the mammary adenocarcinomas. Most of the dierentially expressed genes are increased in p53+/+ tumors and many of these represent known target genes of p53 (p21 WAF1/C1P1
The tumor suppressor p53 transcriptionally regulates a large number of target genes that may aect cell growth and cell death pathways. To better understand the role of p53 loss in tumorigenesis, we have developed a mouse mammary cancer model, the Wnt-1 TG/p53 model. Wnt-1 transgenic females that are p537/7 develop mammary adenocarcinomas that arise sooner, grow faster, appear more anaplastic, and have higher levels of chromosomal instability than their Wnt-1 transgenic p53+/+ counterparts. In this study, we used several assays to determine whether the presence or absence of p53 aects gene expression patterns in the mammary adenocarcinomas. Most of the dierentially expressed genes are increased in p53+/+ tumors and many of these represent known target genes of p53 (p21 WAF1/C1P1 , cyclin G1, alpha smooth muscle actin, and cytokeratin 19). Some of these genes (cytokeratin 19, alpha smooth muscle actin, and kappa casein) represent mammary gland dierentiation markers which may contribute to the inhibited tumor progression and are consistent with the more dierentiated histopathology observed in the p53+/+ tumors. Several dierentially expressed genes are growth regulatory in function (p21, c-kit, and cyclin B1) and their altered expression levels correlate well with the diering growth properties of the p53+/+ and p537/7 tumors. Thus, while tumors can arise and progress in the presence of functioning wild type p53, p53 may directly or indirectly regulate expression of an array of genes that facilitate dierentiation and inhibit proliferation, contributing to a more dierentiated, slow growing, and genomically stable phenotype. Oncogene
Introduction
The p53 tumor suppressor gene is lost or mutated in over half of all human cancers (Levine, 1997; Lozano and Elledge, 2000) . In addition, inactivation of p53 function without loss of p53 structural integrity may occur by a number of dierent mechanisms (Moll and Schramm 1998; Freedman et al., 1999) . Nevertheless, a signi®cant fraction of human tumors arise and progress without incurring mutation or functional loss of p53 activity. In such tumors, retention of p53 activity has important clinical consequences. These tumors often have better prognoses and better responses to chemotherapeutic regimens (Kirsch and Kastan, 1998; Wallace-Brodeur and Lowe, 1999) . Moreover, some tumor types with intact p53 exhibit less anaplastic histopathology, lower proliferation levels, and less chromosomal instability (Donehower, 1996) .
The p53 protein is a transcriptional regulatory factor that responds to a number of cellular stresses, including DNA damage and activated cellular oncogenes (Giaccia and Kastan, 1998) . The activated p53 protein can transactivate a number of genes involved either in cell cycle control or in cell apoptosis pathways (el-Deiry, 1998) . One of the ®rst identi®ed targets of p53 was the p21 WAF1/C1P1 cyclin-dependent kinase inhibitor, which directly interacts with G1 cyclin-cdk complexes and inhibits their activity, and thus is an important component of the p53-mediated G1 arrest checkpoint (el-Deiry et al., 1993; Harper et al., 1993) . Another important p53 target relevant to the apoptotic function of p53 is bax, a pro-apoptotic protein (Miyashita and Reed, 1995) . Recently, the introduction of large scale screening technologies has greatly increased the number of known p53 targets. Using techniques such as serial analysis of gene expression (SAGE) and cDNA array analyses, a library of genes have been assembled that are either upregulated or downregulated by p53 (Polyak et al., 1997; Yu et al., 1999; Zhao et al., 2000) . Some of these genes regulate cell growth or death control, but others appear to be involved in physiological processes not directly related to growth or death (Polyak et al., 1997; Zhao et al., 2000) . Moreover, there is a great deal of heterogeneity in the response of p53 target genes. A number of factors in¯uence the types of p53-responsive genes that are activated or repressed, including p53 levels, the nature of the cellular stress, and the cell type being studied (Yu et al., 1999; Zhao et al., 2000) .
While the SAGE and cDNA array screens have provided powerful tools for the identi®cation of novel p53 target genes, there are potential limitations in the use of such screens. Generally, very high levels of p53 are often produced, which may fail to identify target genes regulated by physiological levels of p53. In addition, cancer cell lines of various types are often used and these cells have other genetic defects which may prevent identi®cation of bona ®de p53 targets. Finally, the experiments are performed in cell culture, and so targets may be missed that result from the activation of p53 in its normal in-vivo context.
To circumvent some of these potential limitations and identify genes regulated by p53 in vivo which might be directly relevant to tumorigenesis, we have utilized a murine mammary cancer model, the Wnt-1 TG/p53 mouse. Wnt-1 TG mice contain several copies of a germline Wnt-1 oncogene driven by a mammary gland speci®c mouse mammary tumor virus promoter (Tsukamoto et al., 1988) . The female Wnt-1 transgenic mice develop early mammary gland hyperplasia and usually succumb to mammary adenocarcinomas between the ages of 3 and 12 months. In order to determine the eects of p53 dosage on mammary tumorigenesis in this model, we crossed the Wnt-1 TG mice to p53-de®cient mice and the Wnt-1 transgenic female ospring were monitored for mammary tumors in the presence and absence of p53 (Donehower et al., 1995) . As shown in Table 1 , the absence of p53 (p537/7) in the presence of the Wnt-1 transgene resulted in mammary tumors that appeared sooner, grew faster, displayed less dierentiated and more anaplastic histopathology, and exhibited more chromosomal instability than their Wnt-1 TG p53+/+ counterparts (Donehower et al., 1995; Jones et al., 1997) . Moreover, these dierences in tumorigenic phenotypes were likely to be due directly to p53 status, since the p53 gene was not mutated or suppressed in the p53+/+ tumors (Donehower et al., 1995) .
Because the p53+/+ and p537/7 Wnt-1 TG mice generate the same type of mammary adenocarcinomas, we decided to compare their gene expression patterns on the hypothesis that dierences in gene expression might be relevant to p53 status and the observed tumorigenic phenotypes. While we believe there are a number of advantages of our in-vivo tumorigenesis model (e.g. a closer approximation to real physiological conditions), there may also be at least three potential limitations not encountered in the in-vitro screens. First, mammary tumors are heterogeneous and not composed solely of tumor cells. They are a mixture of epithelial tumor cells, myoepithelial and stromal components, adipose cells, and blood vessels. However, we have found that the epithelial tumor component usually predominates and thus the other nontumor components should not obscure any strong dierences in gene expression. Second, despite being of identical histopathological type, intertumoral variation may be signi®cant and apparent dierences might be due to such variation rather than p53 status. To address this problem we analysed expression patterns in ®ve to eight dierent tumors of each p53 genotype. Thus, if all or almost all p53+/+ tumors show higher expression levels of a particular gene than is seen in their p537/7 counterparts, then this dierence is likely to be signi®cant. Finally, comparison of end stage p53+/+ and p537/7 tumors will not necessarily identify direct p53 targets. Instead, secondary p53 targets or genes altered in expression due to other genetic changes might be detected. The discovery that many of the dierentially regulated genes in our tumor model are known p53 target genes has reassured us that, in many cases, the dierential expression is likely to be due directly to p53 expression levels.
Using several dierent approaches, we show here that, in addition to altering biological and genetic properties of mammary adenocarcinomas, p53 status aects gene expression patterns. At least seven dierentially expressed genes have been identi®ed in comparing p53+/+ and p537/7 tumors ( Table 2) . Some of the dierentially expressed genes are clearly related to growth control, while others appear to be dierentiation markers. The observed dierential expression patterns of particular genes ®t well with the biological properties of the parental tumors, suggesting that these genes may be a cause rather than an eect of the tumor phenotype. Thus, these results may provide further insights into the role of p53 target genes in the pleiotropic biological eects associated with tumorigenesis. 
Results

Differentially expressed genes identified by differential display PCR
To identify dierentially expressed genes in Wnt-1 TG p53+/+ and Wnt-1 TG p537/7 tumors, we utilized several dierent types of screening methods. RNA dierential display and cDNA array methods were used to randomly screen the tumors for dierentially expressed genes. In addition, Northern blot and RNAse protection assays were employed to investigate speci®c known candidate genes. Each of these approaches revealed dierentially expressed genes. Our ®rst set of experiments employed RNA dierential display PCR to screen tumor RNAs from Wnt-1 TG p53+/+, Wnt-1 TG p53+/7 LOH, and Wnt-1 TG p537/7 tumors (Liang and Pardee, 1992). The Wnt-1 TG p53+/7 LOH tumors are null for p53 because the remaining p53 wild type allele has been deleted during mammary tumorigenesis (Donehower et al., 1995) . A number of candidate fragments were identi®ed by this PCR-based method. An example of a fragment speci®c for the p53+/+ tumor RNAs is shown in Figure 1a .
All fragments identi®ed in this assay were at increased levels in the p53+/+ tumors. These p53+/+ speci®c fragments were then excised from the gel, reampli®ed with the appropriate dierential display primers, labeled with 32 P and used as probes on Northern blots containing total RNAs from ®ve p53+/+ and ®ve p537/7 tumors. Two separate dierential display fragments consistently showed higher hybridization levels in the ®ve p53+/+ tumors. These fragments were cloned and sequenced. The sequences were then compared with the GenBank database and were shown to be identical to two murine genes: alpha smooth muscle actin and kappa casein. The murine cDNA sequences of these two genes were then obtained and used to probe a Northern blot containing total RNAs from eight p53+/+ mammary adenocarcinomas and eight p537/7 adenocarcinomas ( Figure 1b ). Note that while there is heterogeneity in the RNA levels of each gene from tumor to tumor, when the hybridization levels are quantitated and normalized to control probe (GAPDH) hybridization intensity, signi®cant increases in RNA levels of these genes are observed in p53+/+ tumors. Alpha smooth muscle actin RNA levels were on average 4.2-fold higher in p53+/+ tumors compared to p537/7 tumors. Kappa casein had a mean increase of 3.2-fold compared to p537/7 tumors. These dierences were signi®cant at the 0.05 level as measured by t-test.
Differentially expressed genes identified by cDNA array analysis
As an adjunct to the dierential display analyses, we probed array ®lters containing 588 murine cDNAs (from Clontech) with 32 P-labeled cDNA probes prepared from mRNA derived from either p53+/+ or p537/7 tumors. There were two genes that consistently showed dierential expression by this method: ckit and cytokeratin 19 ( Figure 2a ). Both genes showed higher levels of hybridization in the p53+/+ tumors. cDNAs from cytokeratin 19 and c-kit were labeled with 32 P and hybridized to Northern blots containing mRNAs from multiple p53+/+ and p537/7 tumors. Again, while there was considerable heterogeneity in expression levels, the c-kit and cytokeratin 19 genes averaged 2.4-and 2.7-fold increases in expression in p53+/+ tumors compared to p537/7 tumors ( Figure  2b and data not shown). These dierences were found to be signi®cant by t-test.
Examination of known p53 target genes
Those p53 target genes known to regulate growth control were obvious candidates for analysis. The prototype p53 target gene is p21
, a cyclindependent kinase inhibitor (el-Deiry et al., 1993; Harper et al., 1993) . Northern blot analysis of p53+/+ and p537/7 tumor RNAs using a murine p21 WAF1/CIP1 cDNA probe revealed that the p53+/+ tumors averaged 2.3-fold higher levels of p21 compared to the p537/7 tumors (Figure 2c) , consistent with the reduced growth rates observed in the p53+/+ tumors. These dierences were shown to be statistically signi®cant.
Other important cell cycle regulatory proteins are the cyclins. At least two of these, cyclin B1 and cyclin G1, have been shown to be regulated by p53 (Innocente et al., 1999; Taylor et al., 1999; Okamoto and Beach, 1994) . Cyclin B1 appears to be directly repressed by p53 and cyclin G1 has been shown to be upregulated by wild type p53. The cyclin mRNA levels were assessed in p53+/+ and p537/7 tumors by RNAse protection assay using kits speci®c for murine cyclin Figure 1 Dierentially expressed genes in Wnt-1 TG p53+/+ mice and Wnt-1 TG p537/7 mice identi®ed by dierential display PCR and con®rmed by Northern blot hybridization. (a) A representative dierential display PCR product (T1P5b1, arrow) expressed at higher levels in the Wnt-1 TG p53+/+ tumors compared to either Wnt-1 TG p53+/7 LOH or Wnt-1 TG p537/7 tumors. (b) Northern blot results of two genes (alpha smooth muscle actin and kappa casein). Eight dierent tumor RNA samples from each Wnt-1 TG genotype (p53+/+ and p537/7) were loaded. After normalizing to the control RNA (GAPDH) signal, signi®cant increases in RNA levels of these two genes are observed in Wnt-1 TG p53+/+ tumors p53 effects on gene expression in mammary tumors X-S Cui and LA Donehower mRNAs. Interestingly, the only cyclins to show signi®cant dierential expression after normalization to the GAPDH control RNA were cyclin B1 and cyclin G1 (data not shown). The p537/7 tumors averaged 2.3-fold higher cyclin B1 than p53+/+ tumors and p53+/+ tumors showed 1.8-fold elevated levels of cyclin G1 compared to p537/7 tumors. Again, these dierences were found to be signi®cant by t-test.
Differential protein expression levels
To correlate protein expression levels with the dierentially expressed RNAs in the tumors, we performed Western blot analyses on extracts from p53+/+ and p537/7 tumors. Figure 3a shows that all of the p53+/+ tumors show high levels of alpha smooth muscle actin while only one of the six p537/7 tumors shows comparably high protein levels. Likewise, c-kit and cytokeratin 19 protein levels were generally higher in the p53+/+ tumors than their p537/7 counterparts, consistent with the earlier RNA results (Figure 3b ). p53+/+ tumors also showed higher levels of cyclin G1 than p537/7 tumors ( Figure 3c ). Finally, cyclin B1 protein levels were higher in the majority of p537/7 tumors than in p53+/+ tumors (Figure 3d ), again correlating well with the RNA data for this gene.
Immunohistochemistry on tumor sections
The high expression of alpha smooth muscle actin in the p53+/+ tumors was of interest because this protein is known to be an important marker for the myoepithelial compartment of the mammary gland (Gugliotta et al., 1988) . To con®rm whether the higher alpha smooth muscle actin levels indicated a higher number of myoepithelial cells in the p53+/+ tumors, we performed immunohistochemistry with alpha Figure 3 Dierential expression of proteins in Wnt-1 TG p53+/ + and Wnt-1 TG p537/7 mammary tumors as assayed by Western blot analyses. Tumor lysates were subjected to SDSpolyacrylamide gel electrophoresis, followed by transfer to nylon membranes and immunoblotting with antibodies to the various dierentially expressed proteins. Each blot was then stripped and immunoblotted with an antibody to vertebrate actin, which served as a loading control. (a) Alpha smooth muscle actin protein expression in six Wnt-1 TG p53+/+ and six Wnt-1 TG p537/7 mammary tumor lysates. Alpha smooth muscle actin levels were elevated in Wnt-1 TG p53+/+ tumors compared to Wnt-1 TG p537/7 tumors. (b) c-kit and cytokeratin 19 (CK19) proteins in seven Wnt-1 TG p53+/+ and seven Wnt-1 TG p537/7 mammary tumor lysates. The Wnt-1 TG p53+/+ tumors had higher levels of c-kit and CK19 proteins on average compared to their Wnt-1 TG p537/7 counterparts. (c) Cyclin G1 levels in ®ve Wnt-1 TG p53+/+ and ®ve Wnt-1 TG p537/7 mammary tumor lysates. Wnt-1 TG p53+/+ tumors exhibited higher mean levels of cyclin G1 than Wnt-1 TG p537/7 tumors. (d) Cyclin B1 protein levels in six Wnt-1 TG p53+/+ and six Wnt-1 TG p537/7 mammary tumor lysates. Wnt-1 TG p537/7 tumors exhibited higher mean levels of cyclin B1 than Wnt-1 TG p53+/+ tumors , in Wnt-1 TG p53+/+ and Wnt-1 TG p537/7 mammary tumors. Northern blot hybridization shows ®ve tumor RNA samples from each p53 genotype loaded for comparison. After normalizing to control (GAPDH) mRNA levels, p21 WAF1/CIP1 shows signi®cantly higher expression in Wnt-1 TG p53+/+ tumors than in Wnt-1 TG p537/7 tumors smooth muscle actin antibodies on ®xed sections of p53+/+ and p537/7 tumors. As shown in Figure 4 , the staining patterns in the p53+/+ tumors reveal staining around the more organized glandular structures, consistent with a myoepithelial cell localization. In contrast, the staining for alpha smooth muscle actin in the p537/7 tumors is not only reduced in intensity and frequency, but appears in a more random disorganized pattern associated with the tumor stroma. These results are consistent with a more dierentiated structural organization in the p53+/+ tumors than in their p537/7 counterparts.
Discussion
We believe that the Wnt-1 TG/p53 model provides a number of advantages for mechanistic studies on the role of p53 in tumorigenesis. Virtually all of the Wnt-1 TG females develop only mammary adenocarcinomas within 2 ± 9 months either in the presence or absence of p53. In this model, the absence of p53 has been shown to dramatically alter the biological and genetic properties of the Wnt-1-initiated adenocarcinomas. An important question is whether the more aggressive and malignant characteristics of the p537/7 tumors are a direct result of the absence of p53 or an indirect result of the genomic instability promoted by the lack of p53. In this latter scenario, the driving force for tumor initiation and progression would be the increased rate of cooperating genetic lesions in the p537/7 tumors. However, if p53 were playing a more active role in inhibition of tumor growth through its transcriptional regulatory function, then upregulation of p53 growth inhibitory targets and downregulation of p53 growth stimulatory targets might be observed. In fact, the increase in p21 and cyclin G1 levels and decreased cyclin B1 levels observed in the p53+/+ tumors are consistent with a direct role for p53 in modulating tumor growth rates. Moreover, the upregulation of several dierentiation markers in the p53+/+ tumors, some direct targets of p53, suggests that these genes may be contributing to some of the biological properties of the tumors. Finally, the increased activities of the known p53 target genes in the p53+/+ tumors indicates that p53 signaling pathways are intact in these tumors, and that tumors can readily arise in this model in the presence of functional p53.
The dierentially expressed genes that have been identi®ed in this model fall generally into two categories, growth regulatory genes (p21, cyclin G1, cyclin B1, and c-kit) and dierentiation markers (alpha smooth muscle actin, kappa casein, and cytokeratin 19). Some of the other categories of p53 target genes found in cell based screens, such as apoptosis-related Figure 4 Immunohistochemistry on ®xed Wnt-1 TG p53+/+ and Wnt-1 TG p537/7 mammary tumor sections with alpha smooth muscle actin antibodies. Panels (a) and (c) show a representative Wnt-1 TG p53+/+ mammary tumor at 1006and 4006magni®cation, respectively. Panels (b) and (d) show a representative Wnt-1 TG p537/7 mammary tumor at 1006and 4006magni®cation, respectively. The intense brown staining in the glandular structures of the p53+/+ tumors and comparatively low levels of staining in the more disorganized structures of the p537/7 tumors is consistent with the increased levels of alpha smooth muscle RNA and protein in the p53+/+ tumors as assayed by the Northern and Western blot analyses p53 effects on gene expression in mammary tumors X-S Cui and LA Donehower genes and genes which regulate reactive oxygen species formation, have not been identi®ed as dierentially expressed genes in any of our tumor screens. This ®nding agrees with earlier ®ndings by Yu et al. (1999) that the responses by p53 targets can vary considerably from cell line to cell line. Moreover, because in our model p53 is expressed at physiological levels in an in vivo heterogeneous context of mixed cell types, it is not surprising that the range of p53 targets observed is quite dierent from the cell based screens. However, the speci®c nature of the genes that are dierentially expressed in our model is consistent with their playing a direct role in modulating the biological properties of the tumors. The potential relevance of each dierentially expressed gene to the tumorigenesis process is discussed below.
Differentially expressed growth regulatory genes p21 WAF1/CIP1 p21 WAF1/CIP1 is a protypical p53 target gene activated by p53 in response to a variety of cell stresses (Gorospe et al., 1999) . It is a cyclin-dependent kinase inhibitor which has both G1 and G2 checkpoint functions in response to DNA damage (Harper et al., 1995; Dulic et al, 1998; Bunz et al., 1998) . Its higher levels of expression in the presence of p53 may directly reduce tumor growth rates as observed in previous studies on the Wnt-1 TG model. In these studies we found that Wnt-1 TG p21+/7 mammary tumors had dramatically higher growth rates compared to Wnt-1 TG p21+/+ tumors (Jones et al., 1999) . In addition, maintenance of G1 and G2 checkpoints in the p53+/ + tumors (in part through increased p21) may also contribute to the relatively high levels of genomic stability observed in this category of tumors.
Cyclin B1
Cyclin B1 is the major cyclin component of the mitotic cdc2-cyclin B complex initiating mitosis in eukaryotic cells (Musunuru and Hinds, 1997) . It is upregulated in expression in the G2/M phase of the cell cycle. Recently, it has been demonstrated that p53 directly represses transcription of the cyclin B1 gene and thus may aect G2/M transition by reducing intracellular cyclin B1 levels (Innocente et al., 1999; Taylor et al., 1999) . p21 has also been shown to inhibit the kinase activity of the cyclin B1-cdc2 complex (Xiong et al., 1993; Harper et al., 1995) and so p53 may mediate the G2 checkpoint through multiple mechanisms. Such mechanisms may contribute to the reduced rate of cell cycle progression and increased genomic stability observed in the p53+/+ tumors (Donehower et al., 1995; Jones et al., 1997) .
Cyclin G1
Cyclin G1 has been shown to be transcriptionally activated by p53 in response to DNA damage (Okamoto and Beach, 1994) . The role of cyclin G1 in cell cycle control has not been established and published reports are contradictory as to whether cyclin G1 is growth promoting or growth inhibitory (Smith et al., 1997; Shimizu et al., 1998) . Recently, however, it has been shown that overexpression of cyclin G augments the apoptosis process (Okamoto and Prives, 1999) . However, since apoptosis levels are low in the p53+/+ tumors, it is not clear how increased cyclin G1 levels in these tumors might aect their biological properties.
c-kit
c-kit encodes a membrane tyrosine kinase receptor and is not known to be a direct target of p53. Its ligand is stem cell factor, which promotes growth in a number of hematopoietic precursor types (Ashman, 1999) . Mutated versions of kit can be oncogenic and it is expressed at high levels in small cell lung carcinomas (Hibi et al., 1991) . However, in other types of human cancers, such as melanomas, thyroid carcinomas, and breast cancers, c-kit expression was reduced as the tumors progressed from normal tissues to benign lesions to malignant cancers (Natali et al., 1992a (Natali et al., ,b, 1995 . Moreover, ectopic expression of c-kit in breast cancer cells suppressed their growth (Nishida et al., 1996) , indicating that in mammary cells, c-kit may act as a tumor suppressor. Thus, in our mammary cancer model, the increased expression of c-kit in the p53+/+ tumors may not only be a marker for a less malignant status, but may also be directly active in suppressing tumor cell growth rates.
Differentially expressed differentiation markers
Alpha smooth muscle actin Alpha smooth muscle actin is a major component of micro®laments and assists in maintaining cell shape and movement. It has been shown to be a p53 target gene (Comer et al., 1998) and is also a marker for the myoepithelial cell compartment of the mammary gland (Gugliotta et al., 1988) . Alpha smooth muscle actin is downregulated in transformed cells and an inverse relationship between cellular proliferation and alpha smooth muscle actin expression has been widely observed (Leavitt et al., 1985; Owens et al., 1986) . In the p53+/+ tumors, it appears to be highly expressed in myoepithelial cells, a compartment which is present in lower quantities in the p537/7 tumors (Figure 4) . Thus, higher expression levels of this p53 responsive gene is a good indicator of retention of more dierentiated cell types in the p53+/ + tumors. Whether alpha smooth muscle actin has a role in the inhibition of tumor growth rates is unclear.
Cytokeratin 19
Cytokeratin 19 is one of the constituents of the intermediate ®laments of epithelial cells and has recently been shown to be a p53 target gene (Zhao et al., 2000) . Cytokeratin 19 is a widely used luminal cell epithelial marker which is expressed at high levels in both normal and malignant human mammary epithelial cells (Moll and Schramm, 1998) . It is expressed at high levels in many of the p53+/+ tumors, indicating the presence of signi®cant numbers of luminal epithelial cells in the tumors. However, the p537/7 tumors display lower levels of cytokeratin 19 mRNA and protein, indicating that either these tumors have lost most of their luminal epithelial cells or that the luminal epithelial cells in these tumors have somehow lost cytokeratin 19 expression.
Kappa casein
Kappa casein is not considered to be a p53 target, but is a milk protein speci®c for secretory alveolar cells in the mammary gland (Ginger and Grigor, 1999) . It is found at high levels in normal breast tissue, lower levels in benign lesions, and not at all in invasive carcinomas (Rudland et al., 1993) . Its increased levels in the p53+/+ tumors are consistent with the relatively dierentiated state of these tumors. It also indicates retention of some functional secretory alveolar cells in the p53+/+ tumors and their loss in the more dedierentiated p537/7 tumors.
Conclusions
The identi®cation of dierentially expressed growthrelated genes in our model is consistent with the observed dierences in tumor growth rates between the p53+/+ and p537/7 mice. Interestingly, three of four of these genes are p53 target genes, indicating that wild type p53 is actively regulating expression of these genes. We hypothesize that such p53 signaling inhibits cell cycle progression in the p53+/+ tumor cells and may be at least partially responsible for their slower growth rate. The retention of G1 and G2 checkpoint control in the p53+/+ tumors may also contribute to the slower growth rate and delayed tumor incidence by preventing genomic instability and the resultant increase in oncogenic mutations.
The higher expression of dierentiation markers in the p53+/+ tumors, such as alpha smooth muscle actin and kappa casein, is consistent with their more dierentiated histopathological appearance. Since these two genes have been associated with myoepithelial and secretory alveolar cell types, respectively, it is likely that such dierentiated cell types are lost in the progression of the p537/7 tumors to a more dedierentiated state. In human breast neoplasms, benign lesions show retention of myoepithelial and secrectory alveolar cells, while in invasive carcinomas they are almost completely lost (Rudland et al., 1993) . Thus, the p53+/+ tumors are likely to represent a more benign stage of mammary tumor progression, while the p537/7 tumors may be models for the more invasive stages of mammary carcinomas.
Another interpretation of the p53+/+ and p537/7 tumor dierences is that they are derived from fundamentally dierent cells of origin. WynfordThomas has noted that about one-third of human invasive ductal breast cancers fall into a more aggressive subgroup which can be de®ned by poor dierentiation, high proliferative rate, and estrogen receptor negativity (Wynford-Thomas, 1997). It was suggested that this subgroup may have arisen from a less-dierentiated breast epithelial type such as a mammary stem cell. Interestingly, this aggressive subgroup of breast cancers has also been shown to correlate with a very high rate of p53 mutation (Thor et al., 1992; Mazars et al., 1992) . The predominant, well-dierentiated`luminal' tumor type in humans and the Wnt-1 TG p53+/+ model may retain wild type p53 because there is little selective advantage for p53 mutation, whereas mutation of p53 in the mammary stem cells may provide a more profound advantage. This model is consistent with the idea that the Wnt-1 TG p537/7 tumors arise from an undierentiated mammary stem cell while the Wnt-1 TG p53+/+ tumors arise from a more dierentiated mammary cell type.
Despite the limitations inherent in doing expression analyses on end stage heterogeneous tumors, dierentially expressed genes were identi®ed in multiple p53+/+ and p537/7 tumors. The dierentially expressed genes that were obtained were either growth regulators or indicators of cell dierentiation status and were consistent with the dierential histopathology and biological properties of the p53+/+ and p537/7 tumors. Moreover, these results and the fact that many of these genes were bona ®de direct transcriptional targets of p53 lends support to our argument that screening of whole tumors is a viable approach for identifying such genes. Further screens with large cDNA arrays should reveal additional dierentially expressed genes. A remaining challenge will be to determine which of these dierentially expressed genes have a direct eect on the biological properties of the mammary adenocarcinomas.
Materials and methods
Tumor samples
The Wnt-1 TG/p53 mammary cancer model from which the mammary tumors have been obtained has been previously described (Donehower et al., 1995) . Wnt-1 TG p53+/+, Wnt-1 TG p53+/7, and Wnt-1 TG p537/7 females were monitored for tumors on a weekly basis from the time of weaning until the ®rst observation of tumors. Four weeks after ®rst observation of a tumor, the tumor bearing animal was sacri®ced and the tumor excised. The skin and connective tissue were removed carefully and part of the tumor was placed in 10% neutral buered formalin and the remainder was frozen in an Eppendorf tube at 7808C. The tumor segment in formalin was then ®xed in paran and hematoxylin and eosin stained slides made from 4 m sections of tumor tissue. These sections were then typed by histopathological examination and virtually all were categorized as Dunn type B mammary adenocarcinomas. In preparation for the various RNA assays described below, mRNA was puri®ed from frozen tumor segments utilizing the Invitrogen mRNA extraction kit according to the manufacturer's speci®cations.
Differential display
The Clontech Delta Dierential Display kit was used to screen tumor RNAs derived from p53+/+ and p537/7 mammary tumors. RNAs from p53+/7 tumors that had lost their remaining wild type p53 allele (p53+/7 LOH) were also utilized. These tumors were similar in their histopathological and biologic properties to p537/7 tumors. The protocols were all performed according to the manufacturer's instructions and will only be outlined here. Initially, the ®rst strand cDNA is synthesized from each of the tumor RNA populations of interest, using murine leukemia virus reverse transcriptase and oligo(dT) as a primer. For dierential display PCR, 10 arbitrary 5' primers (oligo(dT) 9 -NN, where N=A,G, or C) were combined with 10 arbitrary 3' primers randomly in a PCR reaction in the presence of alpha-33 P-dATP. To resolve the PCR-ampli®ed labeled cDNA fragments, a denaturing 5% polyacrylamide/8 M urea gel was used. After electrophoresis, the denaturing gels were subjected to autoradiography and the X-ray ®lms were carefully examined for dierentially expressed bands. Generally, multiple tumor RNAs of each genotype were run in parallel to identify fragments which were consistently overexpressed or underexpressed in a particular genotype. Once dierentially expressed bands were identi®ed, they were excised from the gel, placed in TE buer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and the cDNA fragments were eluted from the gel slice by boiling. The DNA was then reampli®ed using the original 5' and 3' arbitrary primers. 32 P-labeled probes were made from the reampli®ed fragments by the random primed oligo labeling procedure using the Roche High Prime kit and used to probe Northern blots of RNAs from 6 ± 8 p53+/+ and 6 ± 8 p537/7 tumors. Those probes p53 effects on gene expression in mammary tumors X-S Cui and LA Donehower that showed consistent p53 genotype-speci®c overexpression or underexpression were ligated into a Clontech TA cloning vector using the Clontech AdvanTAge PCR cloning kit according to the manufacturer's speci®cations. Positive clones were ampli®ed and sequenced with the M13 forward primer and the Amersham Sequenase kit. About 200 ± 300 base pairs of insert sequences were identi®ed by this method and these were used to probe GenBank in homology searches.
Northern blot hybridization
For Northern blot analysis, the Ambion NorthernMax kit was used according to manufacturer directions. Two mg of mRNA from 5 ± 8 p53+/+ tumors and 5 ± 8 p537/7 tumors were loaded in each well of the agarose gel. After electrophoresis, the separated RNAs were transferred to a Zeta-Probe membrane from Bio-Rad. Labeled 32 P probes for each dierentially expressed gene were hybridized to the membranes. After hybridization, membrane washing, and autoradiography, the band hybridization intensities on the ®lters were quantitated on the Molecular Dynamics Storm 860 Phosphorimager. The ®lters were then stripped and reprobed with a labeled GAPDH probe to provide a normalization control. After autoradiography, this ®lter was also subjected to phosphorimager analysis. Relative hybridization intensities for a particular gene in a tumor were always normalized to the intensity of the GAPDH signal in that tumor to obtain quantitative values.
cDNA arrays
The Clontech Atlas mouse array I with 588 known cDNAs attached to duplicate nylon membranes was used for the cDNA array screen. One mg of mRNA from a p537/7 tumor and a p53+/+ tumor were each reverse transcribed in the presence of alpha 32 P-dATP. The labeled cDNA populations were then each hybridized overnight to the two array ®lters according to the manufacturer's speci®cations. After washing and autoradiography, the hybridization intensity of each of the genes on the ®lter was quantitated by phosphorimager analysis. Spot intensities were then normalized to the intensities of housekeeping genes on the ®lter to estimate relative hybridization levels between the p53+/+ and p537/7 ®lters. Genes that repeatedly showed more than 2.5-fold dierences in hybridization intensity between the two ®lters were assessed for dierential expression by Northern blot hybridization after synthesis of probes by RT ± PCR using gene speci®c primers.
RNAse protection assay
RNA expression levels of 14 cyclin genes in the p53+/+ and p537/7 tumors were assessed using two Pharmingen multiprobe RNAse protection assay kits (mcyc-1 and mcyc-2). 32 Plabeled RNA mouse cyclin probes were generated by T7 RNA polymerase-directed synthesis of 14 dierent cyclin gene templates. The multi-probe set was then hybridized in excess to target RNA (10 mg mRNA for each sample) in solution, after which free probes and other single-stranded RNA are digested with RNAses. The remaining RNAse protected probes were puri®ed, resolved on denaturing polyacrylamide gels, and quanti®ed by phosphorimaging. The quantity of each mRNA species in the original RNA sample could then be determined based on the intensity of the appropriately sized protected probe fragment following normalization to a control probe (GAPDH) used along with the cyclin probes.
Immunoblot assays
Western blot analysis of alpha smooth muscle actin, cytokeratin 19, c-kit, cyclin B1 and cyclin G1 protein was performed from tumor lysates of multiple p53+/+ and p537/7 tumors. For alpha smooth muscle actin protein detection, 20 mg of total tumor lysate was run on an 8% SDS polyacrylamide gel. The gel was transferred to a 0.45 mm pore size nitrocellulose membrane (BA85, Schleicher & Schuell) for 2 h at 75 volts and then blocked with 5% nonfat dry milk in Tris-buered saline with 2% Tween 20 (TBST) overnight at 48C. The blot was incubated with mouse monoclonal antibody for alpha smooth muscle actin (Clone 1A4 from NeoMarkers) diluted at 1 : 1000 in TBST with 1% nonfat dry milk for 1 h at room temperature. After washing three times with TBST, the blot was incubated with goat antimouse IgG2a peroxidase. Protein was detected using the supersignal enhanced chemiluminescence (ECL) system (Pierce). For cytokeratin 19 detection, 50 mg protein lysate was loaded for gel separation. The antibody used for cytokeratin 19 was Clone A53-B from NeoMarkers. Dilution and incubation conditions were the same as for alpha-smooth muscle actin. c-kit antibody (M-14, Santa Cruz) was diluted 1 : 200. Antigoat IgG was diluted 1 : 2000 as secondary antibody. For cyclin B1 detection, 20 mg protein lysate was loaded on an SDS-polyacrylamide gel. After transfer to a nitrocellulose membrane, the blot was incubated with a polyclonal antibody to cyclin B1 (Oncogene Research Ab-3) diluted 1 : 2000. For cyclin G1 analysis, 100 mg of tumor lysate was loaded on a 12% SDS-polyacrylamide gel. Cyclin G1 antibody (C-18, Santa Cruz) was diluted 1 : 200 for the Western blot. Goat anti-rabbit antibody (SC-2030, Santa Cruz) was diluted 1 : 1000 as secondary antibody. Each blot was stripped and reprobed with an antibody against all six isoforms of vertebrate actin (C4, Boehringer-Mannheim) as a loading control.
Immunohistochemistry on tumor sections
Tumor samples were ®xed with neutral buered formalin and embedded in paran. Tumor slides were deparanized, rehydrated, and treated with 3% H 2 O 2 to quench any endogenous peroxidase. Samples were then boiled in 10 mM sodium citrate buer (pH 6) for 10 min to unmask the antigen. After washing with PBS, the slides were blocked with 10% goat serum at room temperature for 30 min and then incubated with 1 : 200 mouse monoclonal antibody (1A4, Neomarkers) at 48C overnight. After warming up to room temperature, the slides were washed with PBS and incubated with 1 : 400 peroxidase-coupled secondary antibody (goat anti-mouse, Boehringer-Mannheim) for 1 h. The antibodyantigen reaction was visualized by DAB staining and counterstained with hematoxylin.
